LifeMD, Inc. (NASDAQ:LFMD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $9.1429.

A number of research analysts have weighed in on LFMD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of LifeMD in a research report on Monday, December 29th. B. Riley Financial cut their target price on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Wall Street Zen upgraded shares of LifeMD from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, December 19th. Finally, KeyCorp lowered their price target on LifeMD from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, November 19th.

LifeMD Price Performance

LifeMD stock opened at $4.40 on Tuesday. The company has a market cap of $211.07 million, a price-to-earnings ratio of 16.92 and a beta of 1.92. LifeMD has a 12 month low of $2.56 and a 12 month high of $15.84. The stock’s 50-day moving average is $3.34 and its 200-day moving average is $4.50.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). The firm had revenue of $46.87 million for the quarter, compared to analysts’ expectations of $48.57 million. LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%. Research analysts anticipate that LifeMD will post -0.56 EPS for the current year.

Institutional Investors Weigh In On LifeMD

A number of large investors have recently modified their holdings of the stock. Aristides Capital LLC acquired a new stake in shares of LifeMD in the fourth quarter valued at about $203,000. Virtu Financial LLC acquired a new position in LifeMD during the 4th quarter worth approximately $155,000. Invesco Ltd. boosted its holdings in LifeMD by 18.8% in the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after acquiring an additional 3,870 shares during the period. XTX Topco Ltd boosted its holdings in LifeMD by 9.0% in the 4th quarter. XTX Topco Ltd now owns 82,360 shares of the company’s stock worth $281,000 after acquiring an additional 6,814 shares during the period. Finally, Millennium Management LLC grew its position in LifeMD by 220.8% in the fourth quarter. Millennium Management LLC now owns 216,836 shares of the company’s stock valued at $739,000 after acquiring an additional 149,234 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.